A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Phase 1/2 Recruiting
245 enrolled
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Phase 1/2 Recruiting
350 enrolled
OCTOPOD
Phase 1/2 Recruiting
44 enrolled
ACTengine
Phase 1/2 Recruiting
375 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
MRD
Phase 1/2 Recruiting
30 enrolled
SELECT-2CAR
Phase 1/2 Recruiting
72 enrolled
RAINFOL-01
Phase 1/2 Recruiting
764 enrolled
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Phase 1/2 Recruiting
124 enrolled
FRAPPE
Phase 1/2 Recruiting
40 enrolled
INX-315-01
Phase 1/2 Recruiting
150 enrolled
MAIA-ovarian
Phase 1/2 Recruiting
60 enrolled
ERADIC8
Phase 1/2 Recruiting
120 enrolled
BetaBart
Phase 1/2 Recruiting
61 enrolled
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Phase 1/2 Recruiting
460 enrolled
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Phase 1/2 Recruiting
205 enrolled
Combination Therapy for Recurrent Ovarian Cancer
Phase 1/2 Recruiting
72 enrolled
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
442 enrolled
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
Phase 1/2 Recruiting
22 enrolled
DUAL-OV-CAR-NK
Phase 1/2 Recruiting
36 enrolled
ADVICE
Phase 1/2 Recruiting
80 enrolled
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
233 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Phase 1/2 Recruiting
182 enrolled
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/2 Recruiting
300 enrolled
CERTIS1
Phase 1/2 Recruiting
695 enrolled
PROOV
Phase 1/2 Recruiting
55 enrolled
A Phase Ib/â…¡ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer
Phase 1/2 Recruiting
110 enrolled
NAPISTAR1-01
Phase 1/2 Recruiting
250 enrolled
PIKALO-1
Phase 1/2 Recruiting
720 enrolled
FONTANA
Phase 1/2 Recruiting
506 enrolled
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/2 Recruiting
147 enrolled
EVEREST-2
Phase 1/2 Recruiting
474 enrolled
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
Phase 1/2 Recruiting
51 enrolled
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Phase 1/2 Recruiting
159 enrolled
MK-3475-D20
Phase 1/2 Recruiting
176 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
EBNK-ST-001
Phase 1/2 Recruiting
83 enrolled
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Phase 1/2 Recruiting
534 enrolled
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Phase 1/2 Recruiting
144 enrolled
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Phase 1/2 Recruiting
112 enrolled
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Phase 1/2 Recruiting
152 enrolled
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Phase 1/2 Recruiting
100 enrolled
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
298 enrolled
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Phase 1/2 Recruiting
27 enrolled
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Phase 1/2 Recruiting
890 enrolled
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Phase 1/2 Recruiting
54 enrolled
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Phase 1/2 Recruiting
612 enrolled
NEODOC
Phase 1/2 Recruiting
10 enrolled
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Phase 1/2 Recruiting
126 enrolled
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
Phase 1/2 Recruiting
50 enrolled